{"id":1352,"date":"2026-03-23T06:29:12","date_gmt":"2026-03-23T06:29:12","guid":{"rendered":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/leqembi\/"},"modified":"2026-04-27T03:45:25","modified_gmt":"2026-04-27T03:45:25","slug":"leqembi","status":"publish","type":"page","link":"https:\/\/kishiwada.tokushukai.or.jp\/en\/departments\/neurology\/leqembi\/","title":{"rendered":"Lecanemab (Leqembi\u00ae) \u2014 Eligibility & Treatment Planning"},"content":{"rendered":"
\n
\n
\n
\n
What we do<\/div>\n
\n Specialist evaluation for early Alzheimer’s disease, amyloid PET, and treatment eligibility\n <\/div>\n<\/p><\/div>\n
\n
Key assessment<\/div>\n
\n Memory symptoms, amyloid pathology, MRI findings, and treatment suitability\n <\/div>\n<\/p><\/div>\n
\n
Treatment options<\/div>\n
\n Lecanemab and Donanemab may be considered in eligible cases\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n

\n Our department provides specialist evaluation for memory concerns and suspected early Alzheimer’s disease.
\n Amyloid PET may be considered when confirmation of amyloid pathology is clinically necessary,
\n especially when disease-modifying treatment such as Lecanemab or Donanemab is being considered.\n <\/p>\n<\/header>\n

\n
\n
\n

First specialist evaluation<\/h2>\n<\/p><\/div>\n
\n

\n Patients with memory concerns, suspected early Alzheimer’s disease,
\n or previous test results from another medical institution may request specialist evaluation.\n <\/p>\n

\n We review symptoms, medical history, medications, prior imaging, cognitive testing,
\n and any previous diagnosis before considering the next step.\n <\/p>\n

\n A referral letter is recommended but not mandatory.
\n If available, please bring MRI or CT reports, previous cognitive test results,
\n medication lists, and any prior amyloid PET or dementia-related testing reports.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n
\n

Amyloid PET assessment<\/h2>\n<\/p><\/div>\n
\n

\n Amyloid PET may be considered when confirmation of amyloid pathology is necessary
\n as part of specialist evaluation for suspected early Alzheimer’s disease.\n <\/p>\n

\n This may be especially relevant when treatment eligibility for Lecanemab or Donanemab
\n needs to be assessed.\n <\/p>\n

\n Amyloid PET is not a general screening test.
\n Its use is determined based on symptoms, cognitive assessment, previous records,
\n MRI findings, and specialist evaluation.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n
\n

About Lecanemab and Donanemab<\/h2>\n<\/p><\/div>\n
\n

\n Lecanemab (Leqembi\u00ae) and Donanemab (Kisunla\u00ae) are disease-modifying therapies
\n that may be considered for selected patients with
\n early Alzheimer’s disease<\/strong> or
\n mild cognitive impairment (MCI) due to Alzheimer’s disease<\/strong>.\n <\/p>\n

\n

Lecanemab (Leqembi\u00ae)<\/strong><\/p>\n

    \n
  • Intravenous infusion every two weeks<\/strong><\/li>\n
  • Targets amyloid plaques in the brain<\/li>\n
  • Requires regular hospital visits and safety monitoring<\/li>\n<\/ul><\/div>\n
    \n

    Donanemab (Kisunla\u00ae)<\/strong><\/p>\n

      \n
    • Intravenous infusion once per month<\/strong><\/li>\n
    • Also targets amyloid plaques<\/li>\n
    • Treatment duration and monitoring depend on clinical findings<\/li>\n<\/ul><\/div>\n

      \n These treatments require repeated visits for infusion and monitoring.
      \n This should be considered in advance, particularly for patients travelling from overseas.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

      \n
      \n

      Who may be considered for treatment<\/h2>\n<\/p><\/div>\n
      \n
      \n
        \n
      • Early-stage symptoms consistent with Alzheimer’s disease<\/li>\n
      • MCI due to Alzheimer’s disease or mild Alzheimer’s dementia<\/li>\n
      • Evidence of amyloid pathology, such as amyloid PET or equivalent testing<\/li>\n
      • Medical condition suitable for infusion treatment and MRI monitoring<\/li>\n
      • Able to attend scheduled treatment and follow-up visits<\/li>\n
      • Support from a caregiver or family member is recommended<\/li>\n<\/ul><\/div>\n

        \n Eligibility is determined individually.
        \n These treatments are not suitable for all patients with memory symptoms or dementia.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

        \n
        \n

        Monitoring and safety<\/h2>\n<\/p><\/div>\n
        \n

        \n Treatment requires regular monitoring.
        \n One important consideration is ARIA<\/strong>
        \n (amyloid-related imaging abnormalities), which is assessed using MRI.\n <\/p>\n

        \n
          \n
        • MRI is required before starting treatment<\/li>\n
        • Follow-up MRI and clinical review are performed during treatment<\/li>\n
        • Patients are advised on symptoms that require urgent assessment<\/li>\n<\/ul><\/div>\n

          \n The monitoring schedule is determined based on clinical findings,
          \n treatment choice, and safety considerations.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

          \n
          \n

          Next steps after evaluation<\/h2>\n<\/p><\/div>\n
          \n

          \n After evaluation, we explain whether amyloid PET, additional imaging,
          \n cognitive testing, or other investigations are recommended.\n <\/p>\n

          \n If treatment is considered appropriate, we explain the proposed treatment schedule,
          \n MRI monitoring plan, possible adverse effects, and follow-up arrangements before initiation.\n <\/p>\n

          \n If Lecanemab or Donanemab is not suitable, alternative management and follow-up will be discussed.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

          \n
          \n

          Appointment<\/h2>\n<\/p><\/div>\n
          \n

          \n Appointments are required in principle.
          \n A referral letter from another medical institution is recommended but not mandatory.\n <\/p>\n

          \n Please bring any relevant records if available, including prior cognitive testing,
          \n MRI\/CT reports, amyloid PET report if already performed, medication list,
          \n and a brief clinical summary from your doctor if possible.\n <\/p>\n

          \n For appointment requests and language support, please see the
          \n Neurology<\/a> page.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n